Hannan Liam M, Dominelli Giulio S, Chen Yi-Wen, Darlene Reid W, Road Jeremy
Institute for Breathing and Sleep, Austin Hospital, Heidelberg, Victoria, Australia; University of Melbourne, Medicine, Dentistry and Health Sciences, Melbourne, Victoria, Australia; University of British Columbia, Respiratory Division and Department of Medicine, Vancouver, British Columbia, Canada.
University of British Columbia, Respiratory Division and Department of Medicine, Vancouver, British Columbia, Canada.
Respir Med. 2014 Feb;108(2):229-43. doi: 10.1016/j.rmed.2013.11.010. Epub 2013 Nov 20.
This systematic review examined the effect of non-invasive positive pressure ventilation (NIPPV) on patient reported outcomes (PROs) and survival for individuals with or at risk of chronic respiratory failure (CRF).
Randomised controlled trials (RCTs) and prospective non-randomised studies in those treated with NIPPV for CRF were identified from electronic databases, reference lists and grey literature. Diagnostic groups included in the review were amyotrophic lateral sclerosis/motor neuron disease (ALS/MND), Duchenne muscular dystrophy (DMD), restrictive thoracic disease (RTD) and obesity hypoventilation syndrome (OHS).
Eighteen studies were included and overall study quality was weak. Those with ALS/MND had improved somnolence and fatigue as well as prolonged survival with NIPPV. For OHS, improvements in somnolence and fatigue, dyspnoea and sleep quality were demonstrated, while for RTD, measures of dyspnoea, sleep quality, physical function and health, mental and emotional health and social function improved. There was insufficient evidence to form conclusions regarding the effect of NIPPV for those with DMD.
This review has demonstrated that NIPPV influences PROs differently depending on the underlying cause of CRF. These findings may provide assistance to patients and clinicians to determine the relative costs and benefits of NIPPV therapy and also highlight areas in need of further research.
本系统评价研究了无创正压通气(NIPPV)对慢性呼吸衰竭(CRF)患者或有CRF风险的患者报告结局(PROs)及生存的影响。
从电子数据库、参考文献列表和灰色文献中识别接受NIPPV治疗CRF患者的随机对照试验(RCTs)和前瞻性非随机研究。纳入评价的诊断组包括肌萎缩侧索硬化症/运动神经元病(ALS/MND)、杜氏肌营养不良症(DMD)、限制性胸壁疾病(RTD)和肥胖低通气综合征(OHS)。
纳入18项研究,总体研究质量较差。ALS/MND患者使用NIPPV后嗜睡和疲劳情况改善,生存期延长。对于OHS,嗜睡和疲劳、呼吸困难及睡眠质量均有改善;对于RTD,呼吸困难、睡眠质量、身体功能与健康、心理和情绪健康以及社会功能等指标均有改善。关于NIPPV对DMD患者的影响,证据不足,无法得出结论。
本评价表明,NIPPV对PROs的影响因CRF的潜在病因不同而有所差异。这些发现可能有助于患者和临床医生确定NIPPV治疗的相对成本和益处,也突出了需要进一步研究的领域。